CA3214900A1 - Carboxamide pyrolopyrazine and pyridine compounds useful as inhibitors of myt1 and use thereof in the treatment of cancer - Google Patents

Carboxamide pyrolopyrazine and pyridine compounds useful as inhibitors of myt1 and use thereof in the treatment of cancer Download PDF

Info

Publication number
CA3214900A1
CA3214900A1 CA3214900A CA3214900A CA3214900A1 CA 3214900 A1 CA3214900 A1 CA 3214900A1 CA 3214900 A CA3214900 A CA 3214900A CA 3214900 A CA3214900 A CA 3214900A CA 3214900 A1 CA3214900 A1 CA 3214900A1
Authority
CA
Canada
Prior art keywords
inhibitor
optionally substituted
pharmaceutically acceptable
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3214900A
Other languages
English (en)
French (fr)
Inventor
Jimmy FOURTOUNIS
Jordan Young
Cynthia BERNIER
Daniel Durocher
Nicole HUSTEDT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sinai Health System
Repare Therapeutics Inc
Original Assignee
Sinai Health System
Repare Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai Health System, Repare Therapeutics Inc filed Critical Sinai Health System
Publication of CA3214900A1 publication Critical patent/CA3214900A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3214900A 2021-04-07 2022-04-07 Carboxamide pyrolopyrazine and pyridine compounds useful as inhibitors of myt1 and use thereof in the treatment of cancer Pending CA3214900A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163171955P 2021-04-07 2021-04-07
US63/171,955 2021-04-07
PCT/CA2022/050536 WO2022213204A1 (en) 2021-04-07 2022-04-07 Combination therapies including myt1 inhibitors

Publications (1)

Publication Number Publication Date
CA3214900A1 true CA3214900A1 (en) 2022-10-13

Family

ID=83544890

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3214900A Pending CA3214900A1 (en) 2021-04-07 2022-04-07 Carboxamide pyrolopyrazine and pyridine compounds useful as inhibitors of myt1 and use thereof in the treatment of cancer

Country Status (6)

Country Link
US (1) US20240207300A1 (enExample)
EP (1) EP4319752A4 (enExample)
JP (1) JP2024514844A (enExample)
CN (1) CN117729920A (enExample)
CA (1) CA3214900A1 (enExample)
WO (1) WO2022213204A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220035925A (ko) 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
US12435090B2 (en) 2021-10-04 2025-10-07 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
EP4556474A1 (en) * 2022-07-12 2025-05-21 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Compounds as myt1 inhibitors
TW202434253A (zh) * 2022-11-08 2024-09-01 美商薩諾管理公司 週期蛋白ｅ１狀態作為預測性生物標記用於用ｗｅｅ１抑制劑治療癌症之用途
WO2024104282A1 (zh) * 2022-11-14 2024-05-23 捷思英达控股有限公司 一种1H-吡咯并[2,3-b]吡啶衍生物、其制备方法及其在医药上的应用
JP2025538617A (ja) * 2022-11-25 2025-11-28 上海齊魯制藥研究中心有限公司 Ｐｋｍｙｔ１阻害剤、製造方法、医薬組成物及びその使用
EP4638449A1 (en) * 2022-12-22 2025-10-29 Repare Therapeutics Inc. Methods of making 2-amino-1-(3-hydroxy-2,6-dimethylphenyl)-5,6- dimethyl-1h-pyrrolo-[2,3-b]pyridine-3-carboxamide, a myt1 inhibitor
CN120641415A (zh) * 2023-01-20 2025-09-12 杭州英创医药科技有限公司 作为pkmyt1抑制剂的化合物
EP4658293A1 (en) * 2023-01-30 2025-12-10 Ecole Polytechnique Federale De Lausanne (Epfl) Pou5f1b inhibitors
WO2024179948A1 (en) * 2023-02-28 2024-09-06 F. Hoffmann-La Roche Ag Indazole compounds as pkmyt1 kinase inhibitors
AU2024231943A1 (en) * 2023-03-09 2025-10-16 Cancer Research Technology Limited Biarylamide derivatives and their use as pkmyt1 inhibitors
CN121175306A (zh) * 2023-05-12 2025-12-19 智擎生技制药股份有限公司 稠合吡咯环或稠合吡啶环的化合物
CN121358735A (zh) * 2023-07-04 2026-01-16 杭州领业医药科技有限公司 Rp-6306的晶型及其制备方法和用途
WO2025040014A1 (zh) * 2023-08-18 2025-02-27 英矽智能科技知识产权有限公司 并环化合物及其制备方法和用途
EP4777102A1 (en) * 2023-09-14 2026-07-22 Debiopharm International SA Combination of a wee1 inhibitor and a pkmyt1 inhibitor
WO2025060975A1 (en) * 2023-09-18 2025-03-27 Insilico Medicine Ip Limited Novel compounds as pkmyt1 inhibitors and use thereof
IL327457A (en) * 2023-10-02 2026-05-01 Repare Therapeutics Inc MYT1 inhibitors for the treatment of cancers containing mutations resulting from replication checkpoints
AU2024356662A1 (en) * 2023-10-02 2026-04-30 Repare Therapeutics, Inc. Combination therapies including myt1 inhibitors and wee1 inhibitors
WO2025106635A1 (en) * 2023-11-15 2025-05-22 Zeno Management, Inc. Alteration of f-box and wd repeat domain containing 7 (fbxw7) gene as a predictive biomarker for treating cancer with wee1 inhibitors
WO2025121807A1 (ko) * 2023-12-08 2025-06-12 인제대학교 산학협력단 Ezh2 저해제 및 mettl3 억제제를 포함하는 암의 예방 또는 치료용 약제학적 조성물
JPWO2025182927A1 (enExample) * 2024-02-27 2025-09-04
WO2025188680A1 (en) * 2024-03-04 2025-09-12 Cardiff Oncology, Inc. Use of plk1 inhibitor in combination of gemcitabine or carboplatin in treating ovarian carcinoma
WO2025237957A1 (en) * 2024-05-14 2025-11-20 Institut Curie Composition for treatment of estrogen-dependent cancer comprising a mettl-3 inhibitor and a topoisomerase-1 inhibitor
EP4686475A1 (en) 2024-07-31 2026-02-04 Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud - Centro De Investigação Da Fundação Champalimaud Xpg inhibitors for use in the treatment of cancer
WO2026125935A1 (en) * 2024-12-09 2026-06-18 Repare Therapeutics Inc. Methods of treating cancers having fbxw7 mutations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033837A2 (en) * 1998-12-07 2000-06-15 Smithkline Beecham Corporation Myt1 kinase inhibitors
WO2016104777A1 (ja) * 2014-12-26 2016-06-30 国立大学法人九州大学 がんの処置のための方法
CN115811976A (zh) * 2020-04-01 2023-03-17 修复治疗公司 使用myt1抑制剂的方法
ES3067113T3 (en) * 2020-04-01 2026-05-19 Repare Therapeutics Inc N-phenyl substituted indole derivatives as myt1 inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
WO2022213204A9 (en) 2023-11-16
EP4319752A4 (en) 2025-03-26
US20240207300A1 (en) 2024-06-27
JP2024514844A (ja) 2024-04-03
CN117729920A (zh) 2024-03-19
WO2022213204A1 (en) 2022-10-13
EP4319752A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
US20240207300A1 (en) Combination therapies including myt1 inhibitors
EP4126879B1 (en) N-phenyl substituted indole derivatives as myt1 inhibitors for the treatment of cancer
US12435090B2 (en) Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use
US20230158022A1 (en) Methods of using myt1 inhibitors
EP3448386B1 (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
CN107614499B (zh) 吡啶并［3，4-d］嘧啶衍生物及其药学上可允许的盐
CN120712252A (zh) 包含sos1抑制剂和抗癌药物的用于治疗癌症的药物组合物
US20230142913A1 (en) Tricyclic heteroarenes, pharmaceutical compositions containing the same, and methods of using the same
CN114728945B (zh) 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
KR20190099209A (ko) 8,9-디하이드로이미다졸[1,2-a]피리미도[5,4-e]피리미딘-5(6H)-케톤계 화합물
KR20130142153A (ko) 복소환 아민 및 이의 용도
TW200804387A (en) Novel imidazopyrazines as cyclin dependent kinase inhibitors
WO2019089835A1 (en) Diazanaphthalen-3-yl carboxamides and preparation and use thereof
US20250304537A1 (en) Heteroarenes, pharmaceutical compositions containing the same, and methods of using the same
EP3856736B1 (en) Novel compounds as nadph oxidase inhibitors
CN115919859A (zh) 一种杂芳基衍生物的药物组合物及其在医药上的应用
US20230348456A1 (en) Quinazolinones, pharmaceutical compositions containing the same, and methods of using the same
HK40108100A (en) Carboxamide pyrolopyrazine and pyridine compounds useful as inhibitors of myt1 and use thereof in the treatment of cancer
CN120435458A (zh) 取代的喹啉作为改进的nf-kb诱导激酶(nik)抑制剂
HK40005209B (en) Isoquinolin-3-yl carboxamides and preparation and use thereof
HK40005209A (en) Isoquinolin-3-yl carboxamides and preparation and use thereof

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260402

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260402

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260402

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260403

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260403

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260408

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260408

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260408

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260408

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260408

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260408